PFE — Pfizer Inc.

As of 2026-08-27, the market is cautiously neutral: PFE has recovered from the low-$20s to $28.01, but the consensus target is $28.17 and analyst ratings are 15 buy / 23 hold / 1 sell. Positive Q2 adjusted EPS of $0.77, a $500M midpoint revenue guidance raise, and 18% operational growth in non-COVID launched/acquired drugs are offset by a $246M GAAP net loss from a $4.3B impairment, lingering patent-cliff concerns, and uncertainty about dividend sustainability.

The last 12 quarters show a COVID bust followed by a re-acceleration: revenue went from -7.8% YoY in Q1 2025 and -5.9% in Q3 2025 to +5.4% in Q1 2026 and +2.6% in Q2 2026 (or ~5% ex-COVID). GAAP operating margin has recovered to 31.3% in Q2 2026 (4.71B on 15.03B revenue) versus early-2024 prints near 14-30%, but reported net income is still punctuated by non-cash impairments (-$3.34B in Q4 2023, -$1.65B in Q4 2025, -$246M in Q2 2026). The structural story is a base business inflecting upward after the COVID collapse rather than a steady linear improvement, with the patent cliff still a real offset.

On trailing GAAP, PFE looks expensive at 37.0x P/E because TTM EPS of $0.76 is impaired. On 2026 guidance, it is cheap: $28.01 / $2.90 midpoint adjusted EPS is ~9.7x, and ~9.4x on the $2.97 analyst next-FY estimate. P/S of 2.51x is below its 5-year average of 2.86x, and the 7.0% dividend yield is a meaningful valuation floor. Net assessment: fairly valued to modestly undervalued on forward/normalized earnings, not cheap on reported GAAP.

At $28.01, the stock is priced for flat/declining earnings power, not for growth: forward P/E ~9.4-9.7x. The market is implicitly saying the 7% dividend is the return engine and any pipeline/non-COVID upside is a free option. If PFE delivers $2.80-3.00 adjusted EPS and keeps non-COVID growth at high single digits, the current price is below fair value and a move toward 11x forward earnings (~$31-33) is plausible. If patent losses outpace offsets, the cheap multiple is a value trap and dividend coverage becomes the key risk.

As of 2026-08-27, RSI(14) is 64.2, so momentum is positive but not overbought. The stock is 3.96% above its 20-day SMA (approx. $26.94), 9.72% above its 50-day SMA (approx. $25.53), and 7.45% above its 200-day SMA (approx. $26.07), putting it in a clean medium-term uptrend near the 52-week high of $28.75. Chasing here is risky; a pullback toward $27 or $25.50 would offer a better entry for new money.

• A stabilizing/falling rate environment increases relative demand for PFE's ~7% dividend yield from income-focused institutional investors.
• IRA Medicare drug-price negotiation continues to pressure long-run pricing power in small-molecule portfolios.
• The patent cliff is a macro headwind for legacy pharma: Pfizer must replace Eliquis/Ibrance-era revenue with new launches.
• Healthcare sector rotation back into defensive large caps has helped PFE recover from its 52-week low.

• Q3 2026 earnings around Nov 3 - confirmation that non-COVID growth continues and full-year guidance holds or rises.
• Mevrometostat Phase 3 (Mevpro-1) data in mCRPC, expected H2 2026.
• Regulatory/commercial progress on the Valneva-partnered Lyme disease vaccine and Litfulo in vitiligo.
• Continued Seagen/oncology portfolio ramp, led by Padcev, and further productivity savings.

• Patent cliff acceleration in core franchises (Eliquis, Ibrance, etc.) outpacing new-launch growth.
• Dividend sustainability: annual dividend ~$9.8B vs TTM FCF ~$11.0B, leaving thin coverage; Q2 2026 FCF was only $302M and cash is just $976M against $60.5B LT debt.
• IRA/pricing policy and Medicare negotiation eroding future revenue.
• Further COVID revenue cuts or pipeline/regulatory setbacks forcing additional impairments and another guidance reset.

PFE is best framed as an income/value play with a modest turnaround: the non-COVID business is inflecting, the valuation is low on forward earnings, and the dividend yield is high, but the balance sheet/FCF cushion is thin and the patent cliff is real. As of 2026-08-27 I view it as a reasonable hold and an accumulate-on-weakness candidate, not an urgent buy at $28.01.

I applied a justified forward P/E of 10.5x to next-FY EPS of ~$2.97, a modest re-rate from the current ~9.4x multiple to reflect improving non-COVID growth and the 7% dividend yield; this is consistent with applying PFE's 5-year average P/S of 2.86x to next-FY revenue of ~$62.2B (about $31.2 per share), while patent-cliff/IRA risks cap the multiple.